Enoxaparin thromboprophylaxis in gastric bypass patients: extended duration, dose stratification, and antifactor Xa activity.
about
The Anti-Factor Xa Range For Low Molecular Weight Heparin ThromboprophylaxisPrevention of venous thromboembolism in patients undergoing bariatric surgeryMeasuring anti-factor xa activity to monitor low-molecular-weight heparin in obesity: a critical reviewAppropriate enoxaparin dose for venous thromboembolism prophylaxis in patients with extreme obesity.Prevention of venous thromboembolism in obesity.Clinical and critical care concerns in severely ill obese patient.Prophylaxis of venous thromboembolism with low molecular weight heparin in bariatric surgery: a prospective, randomised pilot study evaluating two doses of parnaparin (BAFLUX Study).Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings.Anticoagulating obese patients in the modern era.Perioperative management of the severely obese patient: a selective pathophysiological review.Pharmacologic prevention of venous thromboembolism in obese patients.Chemical prophylaxis to prevent venous thromboembolism in morbid obesity: literature review and dosing recommendations.The use of anticoagulants for the treatment and prevention of venous thromboembolism in obese patients: implications for safety.3rd Guideline for Perioperative Cardiovascular Evaluation of the Brazilian Society of Cardiology.Fixed-dose enoxaparin after bariatric surgery: the influence of body weight on peak anti-Xa levels.Clinical markers of the hypercoagulable state by rotational thrombelastometry in obese patients submitted to bariatric surgery.Pharmacokinetics of rivaroxaban after bariatric surgery: a case report.A randomized controlled trial of differing doses of postcesarean enoxaparin thromboprophylaxis in obese women.Perioperative management of the obese surgical patient.Use of Enoxaparin in Obese Adolescents During Bariatric Surgery--a Pilot Study.Mandatory Risk Assessment Reduces Venous Thromboembolism in Bariatric Surgery Patients.Anti-Xa Levels 4 h After Subcutaneous Administration of 5,700 IU Nadroparin Strongly Correlate with Lean Body Weight in Morbidly Obese Patients.Population pharmacodynamic model for low molecular weight heparin nadroparin in morbidly obese and non-obese patients using anti-Xa levels as endpoint.Implementation of an enoxaparin protocol for venous thromboembolism prophylaxis in obese surgical intensive care unit patients.Efficacy and safety of high-dose thromboprophylaxis in morbidly obese inpatients.Adjusted-Dose Enoxaparin for VTE Prevention in the Morbidly Obese.Profilaxia do tromboembolismo venoso em cirurgia bariátrica.Low-Molecular-Weight Heparin Prophylaxis Dosing: Is Weight an Issue?Profilaxia da trombose venosa profunda em cirurgia bariátrica: estudo comparativo com doses diferentes de heparina de baixo peso molecular.Prevenção do tromboembolismo na cirurgia do câncer do aparelho digestivo
P2860
Q26770822-104D10F5-9C5A-4182-AB80-9879A3B278B2Q26796429-E92C2E3D-71F5-43EF-8066-27CCFA8C4ECEQ26992262-755CA354-2DE7-47AE-8360-66430B5C8DD1Q34612869-A86B23D0-8B0B-4EAF-9F1E-4D841014E032Q35633708-D3259DB4-5FB8-4181-A20B-02557235DF86Q36331619-AEEB0459-3C7B-4B8B-AE7F-760FC5B105B5Q37453595-02A5E2CE-D475-4CE3-9C9C-DF97D60C96EBQ37490581-0D50A5E7-77FB-4AFC-A630-C437E9D8799EQ37919151-25BDAFD1-3307-4AFB-AE51-0AEB56F98909Q38029544-DBA2FD97-98C8-4D40-A068-E8503BF175F9Q38062477-D8CEA8EA-C1AA-4E68-803E-2C9008B6372DQ38485825-B232614B-246A-43EC-91A2-C310B0F2A651Q38633482-EE8D9C54-0D8C-4CF3-993A-3A454208B502Q42134079-E2D681BB-9DF8-4E58-A922-17BAF5BF150EQ43426032-64C39110-C125-4E15-9E7D-624335AEAE82Q44926539-17A6BE37-F2B1-4226-A410-89C2505290E7Q45727029-26DA50AA-D9C5-4C75-A85E-B465409201DAQ46105580-5A2A267E-51C9-4C28-82FE-49D36B9B4897Q46440837-9CF05CEB-6879-4543-A24C-EE80410E252BQ46618514-3EBED8D0-A8EE-4576-A28A-E44CB3D3B61AQ47289421-40B1EBC5-5E5B-4391-95B9-6C8D057C9CD8Q47328313-52B9A0F8-DEB8-4B5B-BF3B-870C6F633128Q47431339-5A91A386-5E1B-4810-90E6-0FE8EBAAB860Q50999671-AB3A88EB-C91A-4286-AE0F-81B62F93EF66Q53101380-5548D2FE-3B22-4B49-B72E-4BFDC90BD7E7Q55235456-102C0FB9-5021-4B58-8434-B1D7D1420A3FQ55257403-BA6A89C6-B70B-439A-B794-E18352F49360Q55261242-1E0C55C5-E25F-46F0-8A8A-43A4C5F61EAAQ55265375-0B82FF0A-5B57-440B-A461-F6B3D9BD9AB1Q58861106-8E37A062-544D-45E1-B5DF-C92A80FEC50F
P2860
Enoxaparin thromboprophylaxis in gastric bypass patients: extended duration, dose stratification, and antifactor Xa activity.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Enoxaparin thromboprophylaxis ...... n, and antifactor Xa activity.
@en
Enoxaparin thromboprophylaxis ...... n, and antifactor Xa activity.
@nl
type
label
Enoxaparin thromboprophylaxis ...... n, and antifactor Xa activity.
@en
Enoxaparin thromboprophylaxis ...... n, and antifactor Xa activity.
@nl
prefLabel
Enoxaparin thromboprophylaxis ...... n, and antifactor Xa activity.
@en
Enoxaparin thromboprophylaxis ...... n, and antifactor Xa activity.
@nl
P2093
P1476
Enoxaparin thromboprophylaxis ...... n, and antifactor Xa activity.
@en
P2093
James M Kane
John E Pantano
Marilyn J Borkgren-Okonek
Nancy C Sambol
Nancy Gordon
Paul J Guske
Peter C Rantis
Robert W Hart
P304
P356
10.1016/J.SOARD.2007.11.010
P577
2008-02-08T00:00:00Z